Home » Newsletters » BioWorld Science

BioWorld Science

April 16, 2009

View Archived Issues

Rosuvastatin reduces high sensitivity C-reactive protein and LDLC

Effects of bivalirudin in HORIZONS-AMI trial independent of clopidogrel dose

Novel MEK inhibitors identified by Curis

Abbott describes novel prodrugs of a histamine H3 receptor ligand

T-type calcium channel inhibitors claimed by Ewha Womans University as analgesics

Boehringer Ingelheim claims novel calcitonin gene-related peptide antagonists

Arete Therapeutics presents epoxide hydrolase inhibitors for the treatment of hypertension

First human pharmacokinetic data for anticancer agent KP-1019 reported

Merck & Co. and Santen enter licensing agreement for tafluprost

Pro-Pharmaceuticals' Davanat was not associated with mucositis in phase I and II trials

Pfizer and Medivation initiate phase III trial of Dimebon added to donepezil in AD patients

Novel corticotropin-releasing factor receptor antagonists developed as anxiolytics

Cannasat and IntelGenx report phase Ib results for buccal dronabinol

Etanercept to be studied in Kawasaki disease / News in Context

Infinity stops RING trial in advanced GIST, clinical trials to continue in other cancers

Novagali completes phase II Cyclokat trial in dry eye

Vyteris and Zealand Pharma sign collaboration agreement in transdermal peptide delivery

Tekmira files IND with FDA for phase I clinical trial of ApoB SNALP for LDL cholesterol

Asahi Kasei and Dong-A sign license agreement for BPH drug Flivas

XenoPort exercises co-promotion option contained in agreement with GSK for Solzira

Accera forms wholly owned subsidiary, Neuera Pharmaceuticals

Sirion reports interim phase II results for fenretinide

Ensemble forms alliance with Bristol-Myers Squibb to develop novel drug class

Cangene to supply the U.S. Department of Defense with VIG vaccine

Clinuvel provides update on afamelanotide

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...